了解卢旺达的疟疾治疗坚持:对素耐药性的影响
Pierre Gashema1,2, Aileen Jordan1, Eric Saramba3
1College of Medicine and Veterinary Medicine, University of Edinburgh.
medRxiv : the preprint server for health sciences
|August 8, 2025
概括
尽管卢旺达的疟疾知识很高,但发烧患者的治疗坚持不佳是一个重大问题. 这种缺乏坚持加剧了抗疟疾药物耐药性的风险,需要紧急干预.
科学领域:
- 公共卫生 公共卫生
- 传染性疾病 传染性疾病
- 全球健康 全球健康
背景情况:
- 及时诊断和治疗疟疾是重要的干预措施.
- 卢旺达新出现的抗素耐药性突显出需要最佳的社区治疗实践.
- 社区的知识和坚持显著影响疟疾治疗结果.
研究的目的:
- 检查卢旺达政府诊所的发烧患者的疟疾知识,态度和实践 (KAP).
- 确定影响疟疾治疗实践和遵守的因素.
- 在抗疟疾耐药性上升的背景下,解决疟疾治疗方面的挑战.
主要方法:
- 在卢旺达中等到高疟疾传播地区的六个卫生机构进行了横截面研究.
- 406名发烧患者或发烧儿童的照顾者被招募并使用半结构化问卷进行了采访.
- 数据收集发生在2023年12月至2024年2月.
主要成果:
- 观察到高度的疟疾知识:81%的人识别了症状,72%的人了解传播,74.6%的人知道控制措施.
- 尽管知识丰富,但只有46%的受治疗者完成了为期3天的抗疟疾疗程.
- 缺乏坚持 (早期或晚期停止治疗) 是普遍存在的,27%的人服用抗疟疾药物治疗发烧,通常从药店获得.
结论:
- 卢旺达的高疟疾知识并不能转化为一致的治疗坚持.
- 对抗疟疾药物治疗方案的不良遵守是导致药物耐药性风险的关键因素.
- 迫切需要有效的干预措施,以改善撒哈拉以南非洲地区的抗疟疾坚持,特别是记录有耐药性的地区.
相关概念视频
Pulmonary Tuberculosis V
239
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
239
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


